本8-K表格报告及其附件基于新闻稿陈述，如实呈现了TNF制药公司的信息披露内容。该公司股票（代码：TNFA）在纳斯达克资本市场上市，公司始终致力于保持透明度，并就其研发活动与利益相关方保持定期沟通。目前该股票的市净率仅为0.06倍， InvestingPro分析显示该股票可能被低估 。 InvestingPro 订阅者可以获取TNFA的12条额外投资建议和全面的财务指标。

Serum TNF levels following LPS stimulation were also reduced using this gene silencing method. LPS injection is normally lethal, but treatment with siRNA-loaded particles protected mice by ...

The birds-eye-view camera angle on "Thursday Night Football" Prime Vision fully showcases New York Jets wide receiver Garrett Wilson's ridiculous touchdown snag. Watch the highlights from Super ...

BALTIMORE--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to ...

GMP Human TNF-alpha Protein (Cat. No. GMP-TNAH23) is expressed in human 293 cells (HEK293) and comprises amino acids Val 77 to Leu 233 (Accession # P01375). This protein has no "tag". It has a ...

Patients with axial SpA treated with TNF inhibitors had lower risk for hip and/or spine fracture vs. NSAIDs. The finding could influence shared decision-making around treatment choice. TNF ...

BALTIMORE--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to ...

About a third of ulcerative colitis patients inadequately respond to anti-TNF drugs, necessitating treatment with other biologics or with JAK inhibitors, the researchers wrote. "Further research ...